ValuEngine upgraded shares of Immunomedics (NASDAQ:IMMU) from a hold rating to a buy rating in a report issued on Thursday.
A number of other brokerages have also issued reports on IMMU. Zacks Investment Research lowered shares of Immunomedics from a hold rating to a sell rating in a research note on Saturday, February 17th. Jefferies Group boosted their price target on shares of Immunomedics from $22.00 to $27.00 and gave the stock a buy rating in a research note on Wednesday, January 24th. BidaskClub upgraded shares of Immunomedics from a hold rating to a buy rating in a research note on Friday, December 22nd. Finally, TheStreet upgraded shares of Immunomedics from a d rating to a c- rating in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $19.00.
Shares of NASDAQ:IMMU traded down $0.80 on Thursday, reaching $16.12. The company’s stock had a trading volume of 679,744 shares, compared to its average volume of 2,216,917. Immunomedics has a 52-week low of $5.00 and a 52-week high of $18.93. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.26 and a current ratio of 1.26. The stock has a market capitalization of $2,622.54, a price-to-earnings ratio of -20.11 and a beta of 1.62.
Immunomedics (NASDAQ:IMMU) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.09). The firm had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.90 million. research analysts forecast that Immunomedics will post -0.96 EPS for the current fiscal year.
In other news, Director David M. Goldenberg sold 20,000 shares of the business’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $17.50, for a total transaction of $350,000.00. Following the transaction, the director now directly owns 1,774,285 shares in the company, valued at $31,049,987.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David M. Goldenberg sold 17,729 shares of the company’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $17.09, for a total transaction of $302,988.61. Following the transaction, the director now owns 1,774,285 shares in the company, valued at $30,322,530.65. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 77,729 shares of company stock worth $1,342,589. Company insiders own 14.80% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Calton & Associates Inc. acquired a new stake in shares of Immunomedics in the fourth quarter valued at approximately $135,000. Xact Kapitalforvaltning AB purchased a new position in shares of Immunomedics during the fourth quarter valued at approximately $193,000. Sapphire Star Partners LP purchased a new position in shares of Immunomedics during the fourth quarter valued at approximately $323,000. SG Americas Securities LLC raised its stake in Immunomedics by 27.2% during the third quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 5,631 shares during the period. Finally, Virtus Fund Advisers LLC purchased a new position in Immunomedics during the fourth quarter worth approximately $456,000. Institutional investors own 74.51% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Immunomedics (IMMU) Upgraded to “Buy” by ValuEngine” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2018/04/13/immunomedics-immu-upgraded-to-buy-by-valuengine.html.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.